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INRODUCTION
Since surgical treatment of breast cancer is determined by 
several prognostic factors including tumor size, lymph node 
metastasis, and negative status of the resection margin, the 
value of breast magnetic resonance imaging (MRI) in breast 
cancer is increasing. The role of breast MRI covers every phases 
of breast cancer management such as early detection, preoper-
ative planning, staging, monitoring neoadjuvant chemothera-
py, and identifying recurrence [1-3]. Compared to other pre-
operative imaging modalities such as mammography and breast 
ultrasound (US), breast MRI has the highest sensitivity in breast 
cancer detection, ranging from 93% to 99%, and the ability to 
detect malignancy that is clinically or radiologically occult [4,5]. 
These advantages have resulted in the widespread use of breast 
MRI for other applications that include evaluation of tumor 
extent, identification of multifocality or multicentricity, screen-
ing for contralateral breast cancer, evaluation of the axillary 
lymph node, and determining the resection margin [2,4]. How-
ever, breast MRI as a preoperative diagnostic modality is asso-
ciated with many limitations such as variable specificity (29% to 
98%) and false positive rates, difficulty of percutaneous biopsy, 
high cost, and the possibility of over-treatment [6,7]. Several 
efforts have been made over the past few years in order to over-
come these limits of breast MRI including introduction of mul-
timodality scores of image interpretation, development of a MRI 
lexicon, and standardization of protocols and indications [8,9]. 
Despite of these attempts, specificity of breast MRI still remains 
lower than desired and is responsible for “decision dilemmas” 
in cases of abnormal lesions revealed by breast MRI that were 
not detected on other conventional imaging modalities. In par-
ticular, it is difficult to determine whether these lesions should 
be followed-up or biopsied. Recently, there were several reports 
that “second-look US” in the diagnostic work-up of MRI-detect-
ed breast lesions is useful [10,11]. It is also useful for breast 
cancer centers that are not equipped to perform breast MRI-
guided biopsy [4]. 
The purpose of this study was to investigate the clinical out-
come of additional lesions identified with breast MRI in breast 
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Purpose: The aim of this study was to investigate the clinical out-
come of additional breast lesions identified with breast magnetic 
resonance imaging (MRI) in breast cancer patients. Methods: A 
total of 153 patients who underwent breast MRI between July 
2006 and March 2008 were retrospectively reviewed. Thirty-three 
patients (21.6%) were recommended for second-look ultrasound 
(US) for further characterization of additional lesions detected on 
breast MRI and these patients constituted our study population. 
Results: Assessment for lesions detected on breast MRI consist-
ed of the following: 25 benign lesions (73.5%), two indeterminate 
(5.9%), and seven malignant (20.6%) in 33 patients. Second-look 
US identified 12 additional lesions in 34 lesions (35.3%) and these 
lesions were confirmed by histological examination. Of the 12 le-
sions found in the 11 patients, six (50.0%) including one contra-
lateral breast cancer were malignant. The surgical plan was altered 
in 18.2% (six of 33) of the patients. The use of breast MRI justified 
a change in treatment for four patients (66.7%) and caused two 
patients (33.3%) to undergo unwarranted additional surgical pro-
cedures. Conclusion: Breast MRI identified additional multifocal or 
contralateral cancer which was not detected initially on conven-
tional imaging in breast cancer patients. Breast MRI has become 
an indispensable modality in conjunction with conventional mo-
dalities for preoperative evaluation of patients with operable breast 
cancer. 
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cancer patients, and to evaluate the usefulness of breast MRI 
as a preoperative diagnostic modality. 
METHODS
A retrospective review was performed using the records of 
161 consecutive breast cancer patients who underwent preop-
erative breast MRI between July 2006 and March 2008. Of these 
161 patients, 7 patients who received neoadjuvant chemother-
apy and a male breast cancer patient were excluded from the 
analysis. Breast MR images were acquired using a 1.5-T system 
(Siemens, Erlangen, Germany) and a dedicated CP breast array 
coil (Siemens). Gadobutrol (Bayer Schering Pharma, Berlin, 
Germany) was injected intravenously at a dose of 0.1 mmol/
kg body weight at a flow rate of 1.5 mL/sec, followed by flush-
ing with 20 mL of saline. The imaging sequence included a T2-
weighted, fat suppression, turbo spin echo (TSE) sagittal image 
sequence followed by a T1-weighted, TSE sagittal image, T1 
fast low angle shot (FLASH) 3D dynamic image. Section thick-
ness was typically 2 mm with a 320×221 matrix and a 280-300 
mm field of view. Subtraction images were obtained by sub-
tracting the pre-contrast images from each of the five sets of 
post-contrast images, on a by pixel-by-pixel basis.
Breast MR images were interpreted by two experienced breast 
radiologists using the Breast Imaging Reporting and Data Sys-
tem (BI-RADS) MRI lexicon [12]. Lesions identified on breast 
MRI were described including morphology (shape, margin, 
and internal architecture), enhancement kinetics (enhancement 
rate, amount, and the shape of time/signal intensity curve), 
and signal intensity of the lesion on T2WI. Additional lesions 
detected on breast MRI were defined as follows: 1) located in 
a different quadrant, 2) separated by at least 1 cm of interven-
ing normal-appearing tissue in the same quadrant, and 3) con-
tiguous but extended at least 4 cm beyond the primary cancer 
in the same quadrant [13]. Depending on the degree of malig-
nant suspicion of the lesion, it was classified as benign (BI-RADS 
Category 2 and 3), indeterminate (BI-RADS Category 4), and 
malignant (BI-RADS Category 5).
In cases of additional lesions detected on breast MRI, patients 
underwent second-look US. US with a 15-MHz linear-array 
transducer (Acuson Sequoia; Acuson, Mountain View, USA) 
was used for bilateral whole breast examination. If an additional 
lesion was identified by second-look US, US-guided core nee-
dle biopsy using a 14-guage spring-loaded automatic biopsy 
device (TSK Laboratory, Tochigi-ken, Japan) was taken in the 
same setting. Annual conventional imaging follow-up was used 
for lesions that were likely benign which were not detected by 
second-look US. Descriptive statistical techniques were used 
to evaluate frequency distribution. SPSS version 11.5 software 
package (SPSS Inc., Chicago, USA) was used for statistical anal-
ysis.
RESULTS
The clinicopathologic characteristics of 153 patients were 
shown in Table 1. Additional 34 lesions on breast MRI were 
found in 33 patients (21.6%) out of 153 patients. Lesions of 20 
patients (60.6%) were included in definition 1 of breast MRI 
additional lesion, lesions of 8 patients (24.2%) were in defini-
tion 2, and lesions of 4 patients (12.1%) were in definition 3. 
One patient (3.1%) had 2 lesions of definition 2 and 3. Twenty-
five lesions (73.5%) were assessed as benign lesions, two (5.9%) 
as indeterminate lesions, and seven (20.6%) as malignant lesions. 
Among 34 lesions, second-look US identified 12 lesions (35.3%): 
6 (50.0%) lesions of definition 1, 4 (33.3%) lesions of definition 
2, and 2 (16.7%) lesions of definition 3. Twenty-two patients 
(66.7%) who were not found to have correlated lesions by sec-
ond-look US were recognized as having benign lesions based 
on breast MRI (Figure 1). Three of 25 benign lesions detected 
on second look US were assigned to two lesions of BI-RADS 3 
and one lesion of BI-RADS 4A.
Twelve additional lesions were found in 11 patients; from 
Table 1. Clinicopathologic characteristics of patients
Characteristics   No. of patients (%)
Age (yr)
   ≤40
   41-50
   51-60
   61-70
   ≥71 
    17 (11.1)
    61 (39.9)
    39 (25.5)
    26 (17.0)
  10 (6.5)
Location
   Right
   Left
   Both 
    68 (44.4)
    82 (53.6)
    3 (2.0)
Operative method
   Mastectomy
   BCS
    68 (44.4)
    85 (55.6)
Histology
   DCIS
   IDC
   ILC
   Others*
  14 (9.2)
  125 (81.7)
    3 (2.0)
  11 (7.1)
TNM Stage
   0
   I
   II
   III
  14 (9.2)
    64 (41.8)
    57 (37.3)
    18 (11.7)
BCS=breast conserving surgery; DCIS=ductal carcinoma in situ; IDC=invasive 
ductal carcinoma; ILC=invasive lobular carcinoma. 
*Mucinous carcinoma, 4 cases; micropapillary carcinoma, 3 cases; invasive 
papillary carcinoma, 1 case; metaplastic carcinoma, 2 cases; medullary carci-
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the result of US-guided core needle biopsy, six lesions (50%) 
were malignant and the other six were benign (Table 2). Three 
of six malignant lesions were invasive ductal carcinoma (IDC), 
two lesions were invasive lobular carcinoma (ILC), and one 
lesion was ductal carcinoma in situ (DCIS) (Table 2). The size 
of the six malignant lesions ranged from 0.3 cm to 1.0 cm with 
a median size of 0.6 cm. One of the six malignant lesions was 
in the contralateral breast (Table 3). Representative breast lesion 
(patient number 6 in Table 3) identified with second-look US 
in patients with an additional breast lesion originally detected 
on MRI is shown in Figure 2. Consequently, surgical plan of 
this patient was changed to total mastectomy.
The surgical plan was changed for six out of the 33 patients 
(18.2%) who had additional lesions found on breast MRI. 
Among six patients confirmed to have malignant lesions by 
biopsy after second-look US, the surgical plan for four was 
changed to total mastectomy (three patients), and additional 
breast conserving surgery (BCS) (one patient). The other two 
patients among six patients with altered surgical plan were 
found to have benign lesions by biopsy, but additional local 
excision (LE) was performed in these individuals to treat con-
tralateral lesions (Table 4). Therefore, change of surgical plan 
was an appropriate choice for four patients (66.7%), but not 
for two patients (33.3%).
DISCUSSION
There is still controversy concerning the usefulness of pre-
operative breast MRI in operable breast cancer patients because 
of false positive rates, cost, and possibility of over-treatment. 
Preoperative breast MRI may also increase patient anxiety 
through further test procedures, waiting for and receiving       
results, additional follow-up investigations such as biopsy, and 
treatment delays. However, in spite of these limitations, the 
diagnostic value of breast MRI as a preoperative evaluation 
modality is increasing. According to a study to examine use-
fulness of preoperative breast MRI, occult breast cancer which 
Table 2. Pathologic outcome of MRI-detected additional lesions
Pathology No. of lesions (%)
Malignant   6 (50.0)
   Invasive ductal carcinoma
   Invasive lobular carcinoma
   Ductal carcinoma in situ
  3 (25.0)
  2 (16.7)
1 (8.3)
Benign   6 (50.0)
   Florid ductal hyperplasia
   Fibrocystic change
   Fibroadenoma
   Nodular adenosis
  2 (16.7) 
  2 (16.7)
1 (8.3)
1 (8.3)
Total   12 (100.0)
MRI=magnetic resonance imaging.
Malignant (n=1) 
Benign (n=2)
No correlates  
on US (n=22)
Malignant (n=4) 
Benign (n=3)
Malignant (n=1) 
Benign (n=1)
Assessment of additional 34 MR lesions  
 in 33 patients*
Benign lesions (n=25) Indeterminate lesions (n=2) Malignant lesions (n=7)
Figure 1. Assessment and pathologic 
results of additional lesions on magnetic 
resonance imaging (MRI). Additional 34 
lesions on breast MRI were found in 33 
patients. Twenty-two lesions which were 
assessed as benign lesion on breast MRI 
were not identified the additional lesions 
on second-look ultrasound (US). Twelve 
additional lesions in 11 patients have 
been diagnosed as follows. 
*One patient has two malignant assessed 
lesions in each breast.
Table 3. Characteristics of patients with malignant lesion
Patient MRI finding
US finding  
(BI-RADS)
Pathology Size (cm) Site
Change of  
surgical plan
1 Benign 3 ILC 0.6 Multifocal  No
2 Indeterminate 4B IDC 0.7 Contralateral Yes 
3 Malignant 4A ILC 1.0 Multifocal Yes
4 Malignant 4C DCIS 0.3 Multifocal No
5 Malignant 4C IDC 0.4 Multifocal Yes
6 Malignant 4C IDC 0.7 Multifocal Yes
MRI=magnetic resonance imaging; US=ultrasound; BI-RADS=breast imaging reporting and data system; IDC=Invasive ductal carcinoma; ILC=invasive lobular 
carcinoma; DCIS=ductal carcinoma in situ.216  Gi-WonHa,etal.
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was not detected clinically or with conventional imaging was 
found by breast MRI in approximately 1% to 18% of the study 
patients [5]. Furthermore, other investigators reported that the 
sensitivity of breast MRI for detecting multicentric disease is 
up to 93%, and the sensitivity for detecting contralateral dis-
ease is up to 88% [4,14]. In addition, non-mass forming lesions, 
which are defined as duct dilatation with internal echoes, multi-
vesicular pattern, and low echo area in the mammary gland on 
breast US, can be more specifically evaluated by breast MRI. 
Sotome et al. [15] reported that breast MRI is useful to find 
breast cancer if the possibility of malignancy of non-mass form-
ing lesion identified by breast US cannot be excluded. Our study 
demonstrated that additional lesions on breast MRI were found 
in 33 (21.6%) out of 153 patients. Among these 33 patients, 
newly-identified additional breast cancer was found in six (3.9%); 
these results were similar to that of previous study [5].  
Although the sensitivity of breast MRI is very high, some 
authors noted that the specificity is relatively limited [6,7]. This 
is because the specificity of breast MRI is affected by various 
factors such as the experience of the radiologist, the use of     
appropriate imaging techniques, and composition of the pa-
tient cohort [16]. Kuhl [1] also reported that for cases of DCIS, 
sensitivity and specificity of breast MRI are much lower than 
that for IDC. The mere detection of DCIS was limited due to 
the fact that enhancement is seen in only a fraction of DCIS 
cases, ranging from 70% to 80%. Therefore, the appropriate 
use of breast MRI for preoperative evaluation is currently one 
of the most debated issues in breast cancer treatment. 
On the other hand, to reduce false positive rates, the findings 
of breast MRI are often correlated with findings from other 
breast imaging modalities. According to LaTrenta et al. [7], 
the likelihood of breast cancer was significantly higher among 
breast MRI-detected lesions with a US correlation (43%) than 
lesions without a US correlation (14%). Shin et al. [17] also   
reported that targeted US can play a useful role in the evalua-
tion of additional suspicious lesions detected by breast MRI. In 
a study by Beran et al. [18], seventy-five additional suspicious 
lesions were detected by breast MRI in 52 out of 191 women. 
Targeted US identified 65 lesions (87%); consequently, targeted 
US may be a reliable method to confirm breast MRI abnor-
malities in breast cancer patients. In our result, 12 lesions of 34 
lesions identified initially on breast MRI (35.3%) were detected 
A B
Figure 2. A 59-year-old woman with known right breast cancer (4-o’clock position) who underwent preoperative breast magnetic resonance imaging 
(MRI). (A) Subtraction axial MR image shows unexpected oval shaped enhancing lesion (arrow) at 3-o’clock position in the right breast. It was classi-
fied as malignant. (B) On second-look ultrasound, 0.7 cm sized, oval, ill defined, and hypoechoic lesion was found at the identical location. Sono-
graphic findings suggest BI-RADS 4C and pathologic result was invasive ductal carcinoma. 
Table 4. Characteristics of patients with altered surgical plan
Patient MRI finding US finding (BI-RADS) Site Altered procedures Pathology
1 Indeterminate 4A Contralateral Additional LE FAD
2 Malignant 3 Contralateral Additional LE FDH
3 Indeterminate 4B Contralateral Additional BCS IDC
4 Malignant 4C Multifocal BCS→TM IDC
5 Malignant 4C Multifocal BCS→TM IDC
6 Malignant 4A Multifocal BCS→TM ILC
Malignant 4A Contralateral Additional LE Adenosis
MRI=magnetic resonance imaging; US=ultrasound; BI-RADS=breast imaging reporting and data system; LE=local excision; FAD=fibroadenoma; BCS=breast 
conserving surgery; IDC=invasive ductal carcinoma; TM=total mastectomy; FDH=florid ductal hyperplasia; ILC=invasive lobular carcinoma.ClinicalOutcomeofMR-DetectedAdditionalLesions 217
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by second-look US. This detection rate is higher than the rate 
(23%) reported by a previous study [7] but lower than rates 
(66-87%) reported by others [18,19]. During follow-up of 22 
patients who were not found with lesion on second-look US, 
no additional lesions were detected on conventional imaging 
modalities until now. 
Due to the high sensitivity of preoperative breast MRI, women 
may be screened for BCS eligibility and thus received more 
extensive surgical treatment (mastectomy or wider excision). 
Houssami and Hayes [5] performed a meta-analysis of 12 ob-
servational studies and reported that breast MRI changed sur-
gical management, generally from BCS to more radical surgery, 
but found no evidence that breast MRI improved surgical treat-
ment or outcomes. It was also reported that preoperative breast 
MRI does not significantly affect the overall rate of incomplete 
tumor excision but the mastectomy rate was increased due to 
the fact that the tumor extent was more widely evaluated with 
this technique than conventional imaging [6]. In contrast, Jin 
et al. [20] determined that among 154 patients who were evalu- 
ated by preoperative breast MRI, surgical plans of 14 patients 
were changed. Surgery for only three of the 14 patients (1.9%) 
was unnecessarily extended. Thus, these results suggested that 
additional multifocal or multicentric lesions could be diagnosed 
by preoperative breast MRI and influence surgical plans. Mann 
et al. [21] also reported that the re-excision rate of preoperative 
breast MRI group in invasive lobular carcinoma patients was 
remarkably lower than those who did not undergo preoperative 
MRI evaluation, and this difference is related to the decrease of 
the final mastectomy rate. Our study showed that the surgical 
plans were changed for six out of 33 patients (18.2%) in whom 
additional lesions were identified by breast MRI. Although sur-
gery for two (33.3%) out of 6 patients was unnecessarily per-
formed, it was an appropriate choice of treatment for four pa-
tients (66.7%). Therefore, we believe that breast MRI provides 
sufficient preoperative evaluation for breast cancer patients.
Fischer et al. [22] demonstrated that the recurrence rate and 
detection rate of contralateral cancer in the preoperative breast 
MRI group are lower than those of patients who did not un-
dergo this evaluation. These results are due to the fact that breast 
MRI can diagnose breast cancer as accurately as US, correlate 
tumor histology through the pattern of time intensity, and iden-
tify the extent of intraductal spread more accurately than con-
ventional imaging techniques [23]. The only evidence from a 
randomized trial regarding the impact of breast MRI on sur-
gical planning comes from one randomized controlled trial that 
was designed to measure the effect of breast MRI on re-excision 
rates as its primary endpoint [24]. In this trial (Comparative 
Effectiveness of MRI in Breast Cancer, COMICE), 1,623 women 
scheduled for BCS were randomly assigned to preoperative 
evaluation with breast MRI or not. Re-excision rates were not 
statistically significant in women randomized to evaluation by 
conventional imaging (19.3%) or breast MRI in addition to 
conventional imaging (18.8%). Furthermore, there is no evi-
dence that breast MRI improves surgical care or prognosis. 
The current study has some important limitations, however, 
mostly stemming from a small number of patients and retro-
spective design. Additionally, we could not include the recur-
rence rate after surgery because of the short follow-up period. 
This is a considerable limitation of our study, so we recommend 
that additional randomized controlled trials with longer follow-
up periods should be carried out. 
In conclusion, preoperative breast MRI was effective in diag-
nosing additional multifocal or contralateral breast cancer which 
was not detected by conventional imaging techniques. There-
fore, we find that breast MRI is a valuable preoperative diag-
nostic modality for operable breast cancer patients.
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